China-based Harbour BioMed (HKG: 2142) has announced receiving approval from the US FDA to initiate a clinical study of its monoclonal antibody (mAb) HBM1007, a fully-human antibody targeting CD73. This marks a significant step forward in the development of innovative therapies targeting this key biomarker.
HBM1007: Mechanism and Development
HBM1007 is generated from Harbour BioMed’s proprietary Harbour Mice H2L2 transgenic mice platform. The antibody targets CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. HBM1007 recognizes unique epitopes on CD73 and operates through dual modes of action. It blocks the enzymatic activity of both membrane-bound and soluble CD73 independently of AMP concentration, ensuring sustained activity in the tumor microenvironment (TME). Additionally, HBM1007 reduces the surface expression of CD73, significantly diminishing both its enzymatic and non-enzymatic functions.
Future Outlook
With this FDA approval, Harbour BioMed is poised to advance HBM1007 through clinical trials, further exploring its potential as a novel therapeutic agent for cancer treatment. The dual-action mechanism of HBM1007 positions it as a promising candidate for addressing significant unmet needs in oncology.-Fineline Info & Tech
